PMID- 35988521 OWN - NLM STAT- MEDLINE DCOM- 20220914 LR - 20220914 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 111 DP - 2022 Oct TI - Eupalinolide B attenuates lipopolysaccharide-induced acute lung injury through inhibition of NF-kappaB and MAPKs signaling by targeting TAK1 protein. PG - 109148 LID - S1567-5769(22)00632-4 [pii] LID - 10.1016/j.intimp.2022.109148 [doi] AB - Acute lung injury (ALI) is a life-threatening disease characterized by severe inflammatory response, which has no pharmacological therapy in clinic. In this study, we found that eupalinolide B (EB), a sesquiterpene lactone isolated from Eupatorium lindleyanum, significantly ameliorated lipopolysaccharide (LPS)-induced ALI in mice, which manifests as reduction in lung injury score, activity of myeloperoxidase, and release of cytokines interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha (TNF-alpha), and monocyte chemoattractant protein-1 (MCP-1). In RAW264.7 murine macrophages, EB effectively inhibited LPS-induced production of nitric oxide (NO) and prostaglandin E2 (PGE(2)) by down-regulating the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2), respectively. Mechanistically, EB not only blocked LPS-induced phosphorylation of inhibitor of nuclear factor kappa B kinase-alpha/beta (IKKalpha/beta), phosphorylation and degradation of inhibitor of nuclear factor-kappa B alpha (IkappaBalpha), and phosphorylation and nuclear translocation of nuclear factor-kappa B (NF-kappaB) P65, but also suppressed LPS-induced phosphorylation of mitogen-activated protein kinases (MAPKs) in vitro or in vivo. Through cellular thermal shift assay and western blotting, EB was demonstrated to target and inactivate transforming growth factor beta activated kinase-1 (TAK1), which is an important upstream kinase for the activation of NF-kappaB and MAPKs pathways. Additionally, EB-mediated actions were markedly abolished by dithiothreitol in LPS-exposed RAW264.7 cells, suggesting a crucial role of the alpha,gamma-unsaturated lactone for the anti-inflammatory activity of EB. In conclusion, our findings showed that EB could effectively alleviate ALI in mice, and attenuate inflammatory response by inhibiting the activation of TAK1, and TAK1-mediated activation of NF-kappaB and MAPKs cascades. CI - Copyright (c) 2022. Published by Elsevier B.V. FAU - Yang, Luyao AU - Yang L AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China; College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. FAU - Chen, Hongqing AU - Chen H AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China; College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. FAU - Hu, Qiongying AU - Hu Q AD - Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. FAU - Liu, Lu AU - Liu L AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, 611137 Chengdu, China. FAU - Yuan, Yun AU - Yuan Y AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China; College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. FAU - Zhang, Chuantao AU - Zhang C AD - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, 610072 Chengdu, China. FAU - Tang, Jianyuan AU - Tang J AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address: tangjianyuan163@163.com. FAU - Shen, Xiaofei AU - Shen X AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address: sxfcd2008@163.com. LA - eng PT - Journal Article DEP - 20220818 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Lactones) RN - 0 (Lipopolysaccharides) RN - 0 (NF-kappa B) RN - 0 (Sesquiterpenes, Germacrane) RN - 0 (eupalinolide B) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinases) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - *Acute Lung Injury/chemically induced/drug therapy MH - Animals MH - Cyclooxygenase 2/metabolism MH - Dinoprostone/metabolism MH - Lactones/pharmacology/therapeutic use MH - *Lipopolysaccharides MH - Mice MH - Mitogen-Activated Protein Kinases/metabolism MH - NF-kappa B/metabolism MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase Type II/metabolism MH - Sesquiterpenes, Germacrane OTO - NOTNLM OT - Acute lung injury OT - Eupalinolide B OT - Lipopolysaccharide OT - Macrophages OT - NF-kappaB and MAPKs OT - TAK1 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/08/22 06:00 MHDA- 2022/09/15 06:00 CRDT- 2022/08/21 18:30 PHST- 2022/04/23 00:00 [received] PHST- 2022/07/19 00:00 [revised] PHST- 2022/08/07 00:00 [accepted] PHST- 2022/08/22 06:00 [pubmed] PHST- 2022/09/15 06:00 [medline] PHST- 2022/08/21 18:30 [entrez] AID - S1567-5769(22)00632-4 [pii] AID - 10.1016/j.intimp.2022.109148 [doi] PST - ppublish SO - Int Immunopharmacol. 2022 Oct;111:109148. doi: 10.1016/j.intimp.2022.109148. Epub 2022 Aug 18.